^
Association details:
| Biomarker: | IFNG-L |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Carteyva (relmacabtagene autoleucel) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China
Published date:
12/31/2020
Excerpt:
This was a single‐arm, open‐label, multicenter clinical trial design evaluating relma‐cel in adult (≥18 years) patients with CD19+ r/r LBCL....Patients who achieved any response had lower baseline levels of serum TNF‐α and responding patients also had lower peak concentrations for TNF‐α and IFN‐γ (p < 0.01; Figure 4C).
DOI:
10.1002/cam4.3686
Trial ID:
